Over the last five years, Portugal has built a reputation as the medical cannabis ‘doorway to Europe’, the go-to hub for countries from North and South America, Asia and Oceania to ship their cannabis to and have it distributed to Europe’s most active markets.
Mamedica has today announced an exclusive partnership with Cookies to offer its premium pharmaceutical products to patients across the UK.
Multi-state operators, or MSO’s, have long represented the biggest and most influential cannabis players in North America. Yet, as that market matures and expansion opportunities dwindle a new trend is emerging – the rise of ‘multi-country operators’ (MCOs).
SOMAÍ Pharmaceuticals, a leading EU-GMP vertically integrated Multi-Country Operator (MCO) specializing in cannabinoid-based medicines, is proud to announce its entry into Switzerland through a strategic partnership with Dascoli Pharma AG, a Switzerland-based pharmaceutical company specializing in the supply, distribution, and professional training of medical cannabis.
SOMAÍ Pharmaceuticals, a leading EU-GMP vertically integrated Multi-Country Operator (MCO) with the most advanced cannabinoid pharmaceutical extract portfolio, has partnered with Pacific Cannovation Company Limited (PACCAN) to transform Thailand into a global hub for high-quality medicinal cannabis.
SOMAÍ Pharmaceuticals is proud to announce a strategic partnership with Releaf, the UK’s fastest-growing medical cannabis clinic, to bring innovative cannabis-based treatments to Releaf’s rapidly expanding patient base.
SOMAÍ Pharmaceuticals (“SOMAÍ”), a leading EU-GMP vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio, is proud to announce its partnership with Georgelle Pharmaceutical Ltd (“Georgelle”), to bring an innovative range of cannabis-based medicines to patients in Ireland.
Cosma S.A., a leader in cannabis-based pharmaceutical advancements, and SOMAÍ Pharmaceuticals, a fully vertically integrated Multi-Country Operator (MCO) in the global medical cannabis markets, are thrilled to announce a strategic partnership that designates Cosma as the Marketing Authorization Holder (MAH) for both Cosma and SOMAÍ’s cutting-edge cannabis-based products.
SOMAÍ Pharmaceuticals (“SOMAÍ”), a fully vertically integrated Multi-Country Operator (MCO) in the global medical cannabis markets, is proud to announce the Mint Oral Solutions product line launch in Australia, Germany, and the UK.
